Document is current
Any future updates will be listed below
-
Authors
Iimura, Yohei https://orcid.org/0000-0002-3473-8244
Baba, Keisuke
Furukawa, Naoki
Ishibashi, Masaaki
Sasuga, Chieko
Ahiko, Yuka
Monma, Satoko
Sakuyama, Naoki
Aikou, Susumu
Shida, Dai
Nojima, Masanori
Kuroda, Seiichiro
Boku, Narikazu
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research (24ck0106978h0001)
The University of Tokyo
- License Information
-
More Information
Article History
Received: 1 July 2025
Accepted: 6 August 2025
First Online: 14 August 2025
Declarations
:
: Narikazu Boku received lecture fees from Bristol Myers Squibb, Eli Lilly & Co., TAIHO PHARMACEUTICAL, CO., LTD., Astellas Pharma Inc.; Yohei Iimura, Keisuke Baba, Naoki Furukawa, Masaaki Ishibashi, Chieko Sasuga, Yuka Ahiko, Satoko Monma, Naoki Sakuyama, Susumu Aikou, Dai Shida3, Masanori Nojima, Seiichiro Kuroda, has no conflict of interest.
: This protocol was reviewed and approved by the certified Clinical Research Review Board of the University of Tokyo (approval number: 2021512SP) prior to conducting the trial. This clinical trial was conducted in compliance with the Clinical Trials Act in Japan and was registered in the Japan Registry of Clinical Trials (jRCT) as jRCTs031220002.
: All patients were required to provide written informed consent.
: Not applicable.
